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We recently reported that reconstitution of lethally 
irradiated BIO mouse recipients with 40xI06 untreated 
WF rat bone marrow cells resulted in stable fully xeno-
geneic chimerism (WF rat _ BIO mouse). In these ani-
mals, the tolerance induced for skin xenografts was 
highly MHC specific in that donor-specific WF rat skin 
grafts were significantly prolonged while MHC-dispar-
ate third-party xenografts were rapidly rejected (me-
dian survival time [MST] = 9 days). We have now ex-
amined whether islet cell xenografts placed under the 
renal capsule of chimeras rendered diabetic with strep-
tozotocin would be accepted and remain functional to 
maintain euglycemia. Animals were prepared, typed for 
chimerism at 6 weeks, and diabetes induced with strep-
tozotocin. Donor-specific WF (RtlA U) islet cell xeno-
grafts were significantly prolonged (MST >180 days) in 
WF _ BIO chimeras, while MHC-disparate third-party 
F344 rat (RtlN) grafts were rejected with a time course 
similar to unmanipulated B10 mice (MST=8 days). The 
transplanted donor-specific islet cells were functional to 
maintain euglycemia, since removal of the grafts at from 
100 to 180 days in selected individual chimeras uni-
formly resulted in return of the diabetic state. These 
data suggest that donor-specific islet cell xenografts are 
accepted and remain functional in mice rendered toler-
ant to rat xenoantigens following bone marrow trans-
plantation. 
Great advances in the field of transplantation have occurred 
in the last two decades. The availability of nonspecific immu-
nosuppressive agents has allowed pancreatic transplantation to 
become an accepted clinical modality for treatment of diabetes. 
The demand for grafts already exceeds the supply: as of Decem-
ber 1990, 477 patients were awaiting a pancreatic graft (1). 
However, a number of technical limitations are associated with 
transplantation of the whole pancreas, resulting in side effects 
including abscess formation, anastomotic leaks, and rejection. 
In recent years, the development of procedures to isolate large 
numbers of purified human pancreatic islets has made it pos-
sible to initiate a new phase of clinical trails in pancreatic islet 
cell transplantation (2-7). Transplantation of pancreatic islet 
cells is now the most specific replacement therapy for treatment 
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of type 1 insulin -dependent diabetes. Because only 1 % of total 
pancreatic tissue is required to cure diabetes (the islet cells), 
transplantation of purified, pancreatic islet cells overcomes the 
associated limitations encountered with transplantation of the 
whole pancreas. 
It is well recognized that both the whole pancreas and pan-
creatic islet cells are highly antigenic (2-14). Although nonspe-
cific immunosuppressive agents have been instrumental in 
control of alloreactivity to transplanted islet cells, rejection 
often still occurs (8-10). Attempts to decrease antigenicity of 
islet cell grafts using in vitro pretreatment of grafts with 
monoclonal antibodies (11-14), in vitro culture protocols (5, 
15-17), ultraviolet irradiation (18-20), microencapsulation 
(21-24), and isolation of hand-picked pure islet cells (25,26) 
have resulted in some improvement in graft survival but have 
not reliably prevented rejection. Two limitations therefore ex-
ist: the supply of grafts does not meet the demand, and rejection 
remains a problem. 
The induction of donor-specific transplantation across a 
species barrier, using bone marrow stem cells to produce chi-
merism, has been suggested as a potential approach to prevent 
rejection of transplanted pancreatic islet xenografts and over-
come the shortage of solid organ grafts available for transplan-
tation. The association between bone marrow chimerism and 
donor-specific transplantation tolerance has been recognized 
for forty years (27--42). The first association between bone 
marrow chimerism and tolerance was reported by Billingham, 
Brent, and Medawar in 1953 when they demonstrated the 
induction of permanent donor-specific transplantation toler-
ance for skin grafts by transplantation of bone marrow cells 
into newborn mouse recipients (27). Subsequently, numerous 
methods to induce similar tolerance in adult recipients using 
bone marrow transplantation have been reported (28-38). 
Monaco et al. demonstrated prolongation of skin allograft 
survival in mice treated with antilymphocyte serum followed 
by a critically timed transfusion of donor bone marrow stem 
cells (30, 31). Similar tolerance for alloantigens has now been 
achieved in a number of other species, including the dog (37) 
and monkey (38). 
Recently, Ildstad et al. developed and characterized a model 
to induce similar donor-specific transplantation tolerance 
across a species barrier through preparation of fully xenogeneic 
chimeras (rat ~ mouse) (43, 44). Engraftment of rat bone 
marrow stem cells in mouse recipients was stable, as evidenced 
by the presence of rat-derived lymphocytes, myeloid cells, plate-
lets, and red blood cells up to 12 months after reconstitution 
with untreated rat bone marrow cells. Survival was excellent 
(>80% at 180 days), and there was no evidence for graft-versus-
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host disease. Fully xenogeneic chimeras specifically accepted 
donor-strain rat skin grafts but were competent to reject MHC-
disparate third-party mouse and rat skin grafts (43, 44). 
The aim of the present studies was to determine whether 
long-term acceptance and function of pancreatic islet cell xen-
ografts could be achieved in fully xenogeneic chimeras without 
requirement for chronic nonspecific immunosuppressive 
agents. We now report the long-term survival and function of 
donor-specific xenogeneic pancreatic islet cells in fully xeno-
geneic chimeras. 
MATERIALS AND METHODS 
Animals. Six to eight-week-old male C57BL/lOSnJ (B10), BlO.BR/ 
Sgn (B10.BR) mice were purchased from the Jackson Laboratory, Bar 
Harbor, ME. Four to eight-week-old male Fischer 344 (F344, RtlN) , 
and Wistar-Furth (WF, RtlAU) male rats were purchased from the 
Harlan Sprague Dawley Company. Animals were housed in a specific 
pathogen-free facility at the Pittsburgh Cancer Institute and in a 
conventional animal facility after islet cell transplantation. 
Fully xenogeneic reconstitution (non-TeD WF __ BlO). Fully xeno-
geneically reconstituted animals were prepared as previously described 
(43,44). Briefly, inbred B10 male mice recipients were lethally irradi-
ated with a single dose of 950R from a cesium source (Nordion). Using 
sterile technique, bone marrow was flushed, with Media 199 (Gibco, 
Grand Island, NY) containing 50 Ill/ml Gentamicin (MEM) from the 
long bones of donors. The marrow was mechanically resuspended in 
MEM by gentle aspiration through an 18-gauge needle, and the sus-
pension filtered through sterile nylon mesh. The cells were then pelleted 
at 1000 RPM for 10 min, resuspended, and counted. Recipient animals 
were reconstituted within 4-6 hr following lethal irradiation via the 
lateral tail veins using a 27-gauge needle and received 40X106 non-
TCD Wistar-Furth (WF -> B10) rat bone marrow cells. 
Characterization of chimeras by flow cytometry. After 28 days, animals 
were typed to document chimerism using flow cytometry with mono-
clonal antibody staining (43, 44). Briefly, peripheral blood was collected 
into heparized plastic serum vials. After thorough mixing, the suspen-
sion was layered over 1 ml of cold Ficoll-Hypaque (Bionetics, Kensing-
ton, MD), centrifuged at 4°C, and counterstained with sandwich when 
required. The anti-WF and anti-H-2b class I monoclonal antibodies 
were determined to be noncrossreactive on the irrelevant species. 
Arbitrary levels on log scale were selected based on the inflection point 
where straining of the control negative population was minimized while 
retaining maximal numbers of positive cells. 
Diabetes. Six weeks after reconstitution, chimeras were made dia-
betic by intravenous injection of streptozotocin (165 mg/kg) via the 
lateral tail vein. Nonfasting plasma glucose levels were determined on 
blood removed from the orbital sinus of the mice. Only mice with 
plasma glucose concentrations exceeding 300 mg/dl for at least 1 week 
were used as islet cell recipients. 
Rat islet isolation and transplantation. Fischer and Wistar-Furth rat 
islet cells were separated by collagenase digestion using a modification 
of the automated method for human pancreatic islet isolation (3, 5). 
Briefly, the pancreatic duct of the rat was cannulated, and 7 ml of 
Hanks solution containing 1 mg/ml collagenase (Boehringer-Mann-
heim, type P, lot 09) was injected. The distended pancreata were then 
placed in a digestion chamber and subjected to 10-15 min of enzymatic 
digestion. The separated islets were purified with Euro-Collins Ficoll 
(Sigma, St. Louis, MO) (densities were 1.108, 1.096, 1.069, and 1.037). 
The purified islets were cultured overnight in medium (RPMI 1640: 
GIBCO, Grand Island, NY; 10% FCS: Hyclone Laboratories, Inc. + 
1% penicillin [100 U/ml] Sigma Chemical Company, St. Louis, MO, + 
streptomycin [100 U/ml]) at 37°C, 5% CO2• The following morning, 
the islet cells were transplanted beneath the left renal capsule. Two 
groups were prepared: 800 WF donor-specific rat pancreatic islets 
(group 1, n=8), or 800 MHC-disparate Fischer (F344) rat islets, were 
placed under the renal capsule. Six BIO mice that did not receive bone 
marrow were transplanted with 800 Wistar rat islets as a control. 
TABLE 1. PBL typing of fully xenogeneic chimeras 
(WF rat -> BIO mouse)" 
Animal % Rat % Mouse Islet cell donor 
1 86.1 14.8 WF 
2 94.0 5.9 WF 
3 60.2 40.5 WF 
4 88.2 12.8 WF 
5 58.6 40.6 WF 
6 60.9 39.1 WF 
7 67.3 32.8 WF 
8 89.2 12.3 WF 
9 94.5 5.5 F344 
10 86.0 14.0 F344 
11 68.2 32.5 F344 
12 95.0 5.2 F344 
13 61.5 40.0 F344 
14 78.4 24.0 F344 
Normal B10 0.1 99.6 NAb 
Normal WF 99.8 0.2 NAb 
a Typing was performed by PBL at 6 weeks using flow cytometry. 
Anti-class I WF-FITC and anti-H2b-FITC were utilized for staining. 
b NA: not applicable. 
The nonfasting plasma glucose levels were determined in all of the 
animals prior to and daily after transplantation. Rejection of the islet 
xenografts was considered to have occurred when the plasma glucose 
concentrations exceeded 200 mg/dl on 3 consecutive days. In animals 
in which that occurred, grafts were removed and examined histologi-
cally. 
Histological studies. Histology of the xenografts in the kidney and 
native pancreas was performed after rejection had occurred or after 
planned nephrectomy and pancreatectomy in normoglycemic recipi-
ents. The histological sections were stained with aldehyde fuchsin and 
hematoxylin and eosin to demonstrate beta cells and immunoperoxi-
dase to detect insulin. 
RESULTS 
Typing of fully xenogeneic chimeras (WF rat ---+ BlO mouse). 
Fully xenogeneic chimeras were prepared in the standard fash-
ion using untreated WF rat bone marrow cells. Prior to the 
induction of diabetes, the recipients were typed for rat lymphoid 
chimerism 30 days following reconstitution. All mice tested 
exhibited xenogeneic rat chimerism when typed for the pres-
ence of rat peripheral blood lymphocytes (Table 1). As in our 
previous experience, chimerism ranged from 60.2% to 95%. 
Long-term survival of rat islet xenografts in fully xenogeneic 
chimeras. After typing for chimerism, diabetes was induced in 
the fully xenogeneic chimeras using streptozotocin. Normal 
BlO mice were also prepared as controls. Daily blood-glucose 
monitoring was performed. All mice developed diabetes as 
evidenced by serum glucose levels over 300 mg/dl for a mini-
mum of 7 days. Although the chimeras remained healthy, they 
exhibited a decrease in body weight compatible with the dia-
betic state. 
Mice that remained hyperglycemic for over 7 days were 
subsequently transplanted with 800 WF donor-specific islet 
cells placed under the renal capsule. Plasma glucose was mon-
itored daily as an assessment of islet cell function. Survival of 
the donor-specific islet cell xenografts was significantly pro-
longed (median survival time [MST]* >180 days) (Fig. 1). 
Recipients became normoglycemic within 2 days following 
placement of the islet cell xenografts. Two animals became 
* Abbreviation: MST, median survival time. 
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FIGURE 1. Life table survival of donor-specific (WF rat) and MHC-
disparate third-party (F344 rat) pancreatic islet xenografts in fully 
xenogeneic chimeras (WF rat ..... BlO mouse). Recipients were followed 
for a minimum of 180 days. 
hyperglycemic 59 and 120 days following transplantation of the 
donor-specific rat pancreatic islets. In these animals, an ipsi-
lateral nephrectomy was performed to allow histological ex-
amination of the islet cell xenografts. Subcapsular fibrosis was 
present at the site of transplantation beneath the renal capsule, 
and mononuclear lymphoid cellular infiltrates were identified. 
No rat islet cells remained. These findings are compatible with 
chronic rejection. The remaining grafts have been functional 
for up to >180 days. 
Specificity of tolerance to rat pancreatic islet in fully xenoge-
neic chimeras (Non- TeD WF ~ B10). To examine the specific-
ity of tolerance to pancreatic islet xenografts in fully xenogeneic 
chimeras, MHC-disparate third-party F344 rat islets were 
transplanted beneath the left renal capsule of the fully xeno-
geneic chimeras. These xenografts were promptly rejected with 
a time course similar to normal B10 mice (MST=8 days), 
suggesting that the specificity of tolerance to rat islet xenografts 
was highly donor-strain specific. Blood sugar levels in the 
recipients initially normalized, suggesting engraftment of the 
islet cells. This was followed by a return of hyperglycemia (Fig. 
2) and histological evidence for acute rejection (data not 
shown). 
To determine that the euglycemic state was supported by the 
transplanted xenogeneic islet cells and not secondary to a 
return of function of the native pancreas, ipsilateral nephrec-
tomy was performed at 100, 120, and 156 days in 3 animals to 
remove the islet cell xenografts. Following removal of the 
xenografts, daily blood sugar monitoring was performed. In all 
animals examined, a return of hyperglycemia occurred from 12 
to 24 hr following removal of the donor-specific xenogeneic 
islet grafts. Figure 3 shows blood glucose measurements for a 
representative animal prior to and following removal of the 
transplanted islets at 100 days. 
Histological examination of xenogeneic islet cells. After ne-
phrectomy, immunohistochemical staining was performed on 
the islet cell xenografts to examine for the production of insulin 
and glucagon as an indication of function. In all tissue sections 
examined, the islet cells appeared healthy, and there was no 
evidence of chronic inflammation. Insulin production was pres-
ent in all tissue sections examined, suggesting that the islet 
cells were functional and able to produce these hormones. 
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FIGURE 2. Mean plasma blood glucose levels (±SEM) in recipients 
of xenogeneic islets. Diabetes was induced by streptozotocin, and after 
?!7 days of hyperglycemia (BS>300 mg/dl) donor-specific (WF) or 
third-party (F344) islet cell xenografts were placed. Two animals be-
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islet cell grafts. Their blood sugar calculations were excluded from 
these calculations at those time points. 
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FIGURE 3. Kinetics of plasma glucose concentration for a repre-
sentative chimera. Diabetes was induced using i.v. streptozotocin treat-
ment at 6 weeks following reconstitution. After documentation of blood 
sugars >300 for 7 days, islet cell xenografts were then placed (day 0), 
and serum glucose determination followed daily. In this animal, the 
islet xenograft was removed on day 110 to demonstrate that the 
euglycemic state was supported by the xenogeneic islets and not the 
native pancreas. 
Further examination of the native pancreas from the trans-
planted animals demonstrated the presence of islet cells, but 
absence of insulin production as assessed by immunoperoxi-
dase, indicating efficacy of the streptozotocin treatment. 
DISCUSSION 
Significant progress has been made in pancreatic transplan-
tation for treatment of diabetes. The use of multimodal non-
specific immunosuppressive agents has allowed relatively good 
control of allograft rejection (5-7). More recently, the trans-
plantation of isolated pancreatic islet cells has emerged as a 
more-focused approach for treatment of diabetes (2-7, 45, 46). 
Using this approach, anastomoses are avoided, and only the 
insulin-producing islet cells are administered. However, rejec-
tion and a shortage of organs persist as two major limitations. 
Although nonspecific immunosuppressive agents have revolu-
tionized the field of transplantation, rejection may occur in 
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spite of their use. This is true for cellular grafts as well as whole 
pancreas allografts. A significantly increased rate of infection 
and malignancy is associated with the use of nonspecific im-
munosuppressive agents. 
A renewed interest in xenotransplantation has emerged as a 
result of the critical shortage of solid organs available for 
transplantation. Transplantation of solid organs or even cell-
ular grafts obtained from another species, such as the pig, has 
been suggested as a possible solution to the current shortage of 
solid organs. It is well recognized that rejection of xenografts 
is usually more vigorous than that for allografts and not con-
trolled by the conventional immunosuppressive agents utilized 
to control alloreactivity (47). In fact, the mechanisms respon-
sible for graft rejection for xenogeneic disparities are not well 
understood and may, in fact, differ from that for alloantigens 
(47,48). Auchincloss et al. recently reported that skin xenograft 
rejection was mediated, for the most part, by CD4+ T lympho-
cytes (47,48). The induction of donor-specific transplantation 
tolerance using bone marrow cells has therefore been suggested 
as one potential approach to overcome these limitations. 
The association between bone marrow chimerism and donor-
specific transplantation tolerance has been recognized for the 
past 40 years (27). Chimeras can be prepared using both lethal 
and nonlethal conditioning protocols, including lethal total-
body irradiation (28), total lymphoid irradiation, (49), ablative 
chemotherapy (50), antilymphocyte serum (36-42). In all these 
models, the induction of systemic donor-specific transplanta-
tion tolerance was achieved as assessed by permanent accept-
ance of donor skin grafts and the presence of specific hypo-
reactivity to donor alloantigens in vitro (51-53). We recently 
reported the induction of similar chimerism and donor-specific 
transplantation tolerance across a species barrier in a model 
for fully xenogeneic chimerism (rat ~ mouse) (43,44). Recon-
stitution of BlO mouse recipients with 40x106 untreated rat 
bone marrow cells resulted in long-term engraftment of rat 
pluripotent stem cells and maturation of rat T lymphocytes in 
the xenogeneic thymic stromal environment of normal irradi-
ated BlO mouse recipients. Using this model, we have now 
determined that pancreatic islet xenografts are permanently 
accepted and remain functional to maintain euglycemia in a 
xenogeneic environment. 
Long-term acceptance of xenogeneic pancreatic islet cells 
resulted when non-hand-picked purified islet cells were trans-
planted into fully xenogeneic chimeras (WF rat ~ mouse) 
rendered diabetic by streptozotocin treatment. Euglycemia re-
sulted within 48 hr following the placement of the cellular 
xenografts under the renal capsule. In order to determine that 
the euglycemic state present in the chimeras was supported by 
the islet cell xenografts and not due to return of function of 
the native pancreas, we performed serial ipsilateral nephrec-
tomy on selected chimeras to remove the transplanted islet cell 
xenografts. In all animals examined from 31f2 to 6 months 
following placement of the xenografts, the diabetic state re-
turned within 24 hr after removal of the graft, further confirm-
ing that the islet cell xenografts were in fact functional and 
responsible for the euglycemic state. Histologically, grafts ap-
peared healthy, and there was evidence for production of both 
insulin and glucagon, suggesting normal function. Most impor-
tantly, there was no evidence for chronic rejection. 
The tolerance induced by fully xenogeneic (rat ~ mouse) 
reconstitution for islet xenografts was highly MHC specific, as 
evidenced by rapid rejection of MHC-disparate third-party 
(F344) grafts. Rat was not seen as "generic" rat but instead as 
specific strain of rat for the transplanted pancreatic islets. 
Similar results were present for skin grafts, where donor-
specific skin xenografts were accepted while third-party rat 
skin grafts were promptly rejected (43,44). The MHC-dispar-
ate islet cell grafts engrafted as evidenced by the presence of 
euglycemia for 4-8 days in individual recipients. However, 
hyperglycemia reappeared as the third-party grafts were re-
jected. Rejection was aiso confirmed histologically by the pres-
ence of inflammatory mononuclear cell infiltrates. 
In 2 ofthe 8 animals, hyperglycemia returned at 59 and 120 
days, respectively. After 3 days of persistent hyperglycemia, the 
grafts were removed and examined histologically. There was 
evidence for chronic fibrosis as well as mononuclear cell infil-
trates, suggesting chronic rejection. In addition, no islet cells 
could be identified. Despite this graft loss, there was no change 
in the level of xenogeneic chimerism. We speculate that this 
effect may be due to islet-specific antigens expressed on islet 
cells but not on the rat bone marrow elements to which the 
mice were rendered tolerant. Skin-specific antigens present on 
skin, but not on lymphoid cells, have been well characterized 
using bone marrow chimeras (54,55). In these studies, chronic, 
gradual skin graft rejection occurred without change in the level 
of donor bone marrow chimerism (54,55). We recently reported 
evidence for similar skin-specific antigens across a species 
barrier in mixed xenogeneic chimeras (mouse + rat ~ mouse) 
(56), and we speculate that similar antigens may be present in 
the islet cell tissue. However, it is of note that in the majority 
of our recipients we do not have evidence for chronic rejection. 
Studies are in progress to further characterize the mechanism 
responsible for this late rejection and to further examine 
whether it is, in fact, due to islet-specific antigens recognized 
across a species barrier. 
The islet cell preparation used for these studies was not 
hand-picked and therefore most closely approximated the cell-
ular grafts currently utilized in human clinical trials at the 
present time. This form of islet cell preparation is well recog-
nized to be of a heterogeneous, highly antigenic composition 
(2-7), and therefore it served as a test of the presence of 
tolerance in fully xenogeneic chimeras. 
In summary, we report long-term survival and function of 
donor-specific pancreatic islet xenografts in fully xenogeneic 
(rat ~ mouse) chimeras. The tolerance induced was highly 
MHC specific, since third-party rat islet grafts were rejected 
with the same time course as that for unmanipulated BI0 
controls. Further studies are in progress to examine the putative 
role of islet-specific antigens and to evaluate whether other 
cellular endocrine xenografts will be similarly accepted and 
remain functional. 
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ORAL DISCUSSION 
DR. NAJI (Philadelphia, Pennsylvania): I have two specific 
questions. Was there any evidence of graft-versus-host disease 
in your recipients, and, secondly, could you tell us the compo-
sition of the rat T cells and whether there was any T cell 
maturation in the thymus of these mice? 
DR. ILDSTAD: We have documented normal T cell matu-
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ration in our chimeras. The rat-derived T cells enter the thymus 
and exhibit an immature profile: CD8 negative, CD4 negative 
without the alpha-beta TCR and CD3. They then go through 
the expected maturational steps and emerge with a mature 
phenotype:Lymphocytes from the chimeras are also functional, 
and the chimeras are functionally tolerant to both the donor 
strains of rat, yet respond in CTL and MLR responses to third 
party. Similarly, they are also specifically tolerant to the recip-
ient strain of mouse. The tolerance we see is a very MHC-
specific tolerance across a species barrier. 
DR. NAJI: Isn't it surprising that the rat cells mature in the 
murine thymus-this is the first time that I think this has been 
demonstrated-in view ofthe fact that you don't really see that 
when you repopulate the SCID mouse with the human PBL? 
DR. ILDSTAD: This is the first demonstration that the 
mouse stromal environment in the thymus is adequate to 
support development of mature T cells from another species. 
We found it surprising as well. 
DR. BRAYMAN (Minneapolis, Minnesota): Is the Wistar-
Furth islet graft a xenograft or an allograft in an animal that 
has been reconstituted with xenogeneic bone marrow? How are 
we considering this if you have a fully xenogeneic chimera 
where the immune system presumably is now of rat origin? 
DR. ZENG: Your question is an important one, and we are 
in the process of evaluating whether it is the rat, mouse, or 
both lymphoid cells that respond to recognize MHC-disparate 
third-party rat. 
DR. HARDY (New York, New York): In relation to this 
question of nomenclature, could you comment on the degree of 
chimerism? Was this a complete 100%? 
DR. ILDSTAD: The chimerism is never 100%. In the fully 
xenogeneic situation presented today, we have rat chimerism 
for multiple lineages, including red cells, platelets, T cells, B 
cells, and macrophages that ranges from 65% to 99% for indi-
vidual animals. The remaining cells of recipient origin seem to 
be radio-resistant cells that are predominantly CD4 positive 
and alpha-beta TCR negative. Other lineages are not present. 
We don't find mouse-derived red cells, platelets, or other line-
ages that would be produced by the mouse stem cell. 
In mixed chimeras, when we administer a mixture of mouse 
plus rat bone marrow, we have observed lineage production 
from both the mouse-derived stem cell and the rat-derived stem 
cell. 
DR. BRAYMAN: Is a fully xenogeneic chimera really an 
allograft response for third-party rat? 
DR. ILDST AD: In a sense that is correct. For fully xenoge-
neic chimeras, it would be the rat cells responding to the third-
party rat graft as an allograft in a xenogeneic mouse environ-
ment. 
DR. AUCHINCLOSS (Boston, Massachusetts): I doubt that 
you have had the opportunity to create this kind of chimera 
followed by an islet transplant in an NOD mouse or a sponta-
neous diabetic mouse. The reason I ask is that you could then 
see whether or not the xenoislets escape whatever the autoim-
mune disease is that causes diabetes. This possibility has been 
suggested as one of the attractive aspects of xenogeneic pan-
creatic islet transplantation. 
DR. ILDST AD: Yes, it is possible that one could overcome 
the autoimmune disease associated with type 1 diabetes with 
xenotransplantation. It is of note that we do not see graft-
versus-host disease in our chimeras even when we give a very 
large dose of spleen cells. Since autoimmune diseases share 
many similarities, it is possible that xenochimerism would also 
be protective against GVHD. 
DR. HARDY: Have you tried to do this with any other type 
ofrodent, for example, guinea pig to the mouse? 
DR. ILDSTAD: Not yet. We plan to begin those studies in 
the near future. We attempted to achieve engraftment of human 
marrow in our mice but were unsuccessful. 
DR. HARDY: This is a little too radical, but the guinea pig 
is a very good model of xenotransplantation. The rat-to-mouse 
has been prolonged indefinitely in terms of islets by various 
types of protocols, including that of my group, by modifying 
the islets themselves. I think the greatest test would be to go 
on to guinea pig-to-mouse; that might clarify Dr. Brayman's 
question. 
DR. RICORDI: Compared with previous models of prolon-
gation of islet xenograft survival, this experiment was different 
because it was possible to prolong xenograft survival despite 
the partial purity of the preparations used for transplantation. 
In fact, the islets were collected from the Ficoll gradients 
without hand-picking. The quality of the preparations was 
therefore similar to what we use in human islet transplants. I 
am not aware of any previous study showing prolongation of 
islet xenograft survival using islets that were not perfectly clean 
or hand-picked. 
DR. HARDY: Dr. Ricordi, your preparation is so good that I 
am sure when it is scaled down to the rat, it's pretty pure. 
DR. RICORD!: But if you perform an analysis of all the 
components, you will find that all of the constituents of the 
pancreas are still present in the purified islet preparation, even 
if their relative percentage is changed. That 10, 20% of contam-
inating non islet component can be very immunogenic. 
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